简介:目的:评估单剂量枸橼酸西地那非片对早期年龄相关性黄斑变性(AMD)男性患者视功能的急性效应。方法:早期年龄相关性黄斑变性男40例,年龄58~86(平均71)岁,前瞻性随机接受安慰剂或者枸橼酸西地那非片(Viagra;PfizerInc,NewYork,NY)100mg,单次口服。受试者双眼在接受药物之前及之后9h内特定的时间间期进行视力、Amsler方格表及辨色力检查。结果:与安慰剂相比,服用枸橼酸西地那非片后视功能检查均未有明显改变。视力和辨色力检查在基线水平上未见有统计意义或临床相关的改变,Amsler方格表检查未见临床相关的改变。服用枸橼酸西地那非片与短暂的轻度至中度头痛和面红有关。结论:单次口服100mg枸橼酸西地那非片,在早期年龄相关性黄斑变性男性样本人群中,耐受性良好,未对视觉产生显著急性效应。
简介:目的研究可降解型VisiPlug泪道栓治疗准分子激光术后干眼的临床疗效。方法选取来我科就诊的23例(46只眼)拟行准分子激光手术且术前伴有轻到中度干眼患者,术后应用VisiPlug泪道栓进行泪道栓塞。分别于准分子激光术前、泪道栓塞术前、栓塞术后2周及3个月,针对于眼症状及泪道栓使用舒适度进行问卷调查,并行角膜荧光素染色、基础泪液分泌试验(SchirmerⅠtest,SⅠt)及泪膜破裂时间(break-uptime,BUT)检查,对疗效进行评价。结果准分子激光术后,患者干眼症状明显加重,SⅠt和BUT明显下降;泪道栓塞术后患者干眼症状明显减轻,SⅠt和BUT明显增加和延长,人工泪液使用频次下降;术后3个月所有患者角膜荧光素染色阴性。随访期间除1只眼栓塞术后1d泪道栓脱落外,无其他并发症发生。结论应用VisiPlug泪道栓可安全、有效地治疗准分子激光术后干眼,增加眼表泪液量,改善泪膜稳定性,缓解干眼症状,替代人工泪液的治疗。(中国眼耳鼻喉科杂志,2011,11:22-25)
简介:AIM:Todeterminethenormativevaluesofwhite-towhitecornealdiameterwithOrbscanIITopographySystemandtocomparerightandlefteyesdatainthenormalyoungpopulation.METHODS:Atotalof1001healthyparticipantsaged18-45yparticipatedinthisobservationalcross-sectionalstudy.Thestudypopulationconsistedof616femaleand385malesubjects.ThecornealdiameterwasmeasuredwiththeOrbscanII.Thedifferencesbetweengenders,betweenrightandlefteyesandage-relatedchangeswereevaluated.StatisticalanalyseswereperformedusingStudent’st-test.RESULTS:Theaveragewhite-to-whitedistanceinourstudypopulationwasrecordedas11.65±0.36mm(median:11.60mm,mode:11.70mm,minimum:10.50mmandmaximum:13.60mm).Thewhite-to-whitedistancewas11.60±0.35mminmalesand11.71±0.36mminfemaleswhichwasstatisticallydifferentbetweengenders(P<0.01).However,white-to-whitedistancewasnotstatisticallydifferentbetweenrightandlefteyes.Inaddition,thisparameterdecreasedwithincreasingage.Considering95%confidenceinterval,cornealdiameterlessthan10.93mmandgreaterthan12.34mmwouldbeconsideredasmicrocorneaandmegalocornea,respectivelybasedonthisstudypopulation,usingtheOrbscanIItopography.CONCLUSION:DetaileddescriptionandanalysisofcornealdiameterwithOrbscandemonstratethattheobtainedaveragevalueofhorizontalwhite-to-whiteishigherinmalethanfemaleanddecreasesslightlywithincreasingage.Ourdataalsosuggeststhecutoffvaluesfordefinitionofmicrocorneaandmegalocornea,whichcanbeemployedwiththispopulation.
简介:目的评价不增加切口的20G标准三通道玻璃体手术治疗严重眼外伤脉络膜上腔出血的疗效。方法对2011年10月至2014年10月间我科收治的29例(29眼)严重眼外伤合并脉络膜上腔出血的病人采取玻璃体手术治疗,置灌注后,通过板层的20G玻切穿刺口引流脉络膜上腔积血,再通过此切口行玻璃体手术,处理玻血和或网膜损伤,术终眼内填充气体或硅油。结果25例患者术中脉络膜上腔出血充分引流完全复位,4例患者残留少量积血,表现为小块脉络膜隆起,注入硅油后,术后一月复查网膜复位。所有患者术后视力均有改善。结论采用不增加切口的三通道玻切的巩膜切口可以有效引流外伤性脉络膜上腔出血,达到理想疗效。
简介:AIM:ToinvestigatetheexpressionsoftypeIcollagen,α2integrinandβ1integrinintheposteriorscleraofguineapigswithdefocusmyopiaandwhetherbasicfibroblastgrowthfactor(bFGF)injectioninhibitstheformationanddevelopmentofmyopiabyupregulatingtheexpressionoftypeIcollagen,α2integrinandβ1integrin.METHODS:After14daysoftreatment,therefractivestateandaxiallengthweremeasuredandthelevelsoftypeIcollagen,α2integrinandβ1integrinwereassayedintheposteriorscleraeofgroupsofguineapigsthatworeamonocular-7Dpolymethylmethacrylate(PMMA)lensorhad-7DlenswearfollowedbytheperibulbarinjectionofPhosphateBufferSolution(PBS)orbFGF.Theuntreatedfelloweyeservedasacontrol.Guineapigswithnotreatmentservedasnormalgroup.·RESULTS:Theresultsshowedthat14daysofmonoculardefocusincreasedaxialeyelengthandrefraction,whilebFGFdeliveryinhibitedthemmarkedly.Further,itwasalsofoundthatthemonocular-7DlenscoulddecreasethelevelsoftypeIcollagen,α2integrinandβ1integrinexpressions,while,unlikePBS,bFGFincreasedthemsignificantlyincomparisontocontralateralcontroleyesandnormaleyes.CONCLUSION:bFGFcanpreventtheformationanddevelopmentofdefocusmyopiabyupregulatingtheexpressionsoftypeIcollagen,α2integrinandβ1integrin.Takentogether,ourresultsdemonstratethatbFGFpromotesscleraremodelingtopreventmyopiainguineapigs.
简介:<正>DearSir,IamDr.YunLi,fromtheSecondHospitalAffiliatedtoNanchangUniversity,JiangxiProvince,China.IwritetopresentacasereportofIOLimplantationin
简介:目的:比较雷珠单抗和光动力疗法(photodynamictherapy,PDT)治疗湿性年龄相关性黄斑变性(age-relatedmaculardegeneration,AMD)的临床疗效。方法:回顾性分析23例PDT治疗的湿性AMD患者和23例予雷珠单抗玻璃体腔内注射治疗的湿性AMD患者的资料,比较两组在治疗后1,3,6mo的视力、OCT及FFA变化情况。结果:两组患者术后1,3mo视力均得到明显提高,两组在统计学意义上无显著差异,雷珠单抗组有2例(9%)患者在治疗后6mo出现视力回降现象,PDT组患者在术后3mo及术后6mo视力变化稳定。结论:雷珠单抗和PDT治疗湿性AMD,均能有效控制湿性AMD患者病情发展并能改善患者视力,两种疗法疗效的比较在短期内无统计学意义,但是术后6mo,PDT的稳定性优于雷珠单抗。